Elvin Pharma was established in 2020 to produce Active Pharmaceutical Ingredient (API). Our goal is to become a trustworthy and internationally preferred company within the pharmaceutical industry.

Our API products include both narcotic and non-narcotic products such as Buprenorphine Hydrochloride, Naloxone HCl, Naltrexone Hydrochloride, Nalbuphine Hydrochloride, Fentanyl Citrate, Bosentan Monohydrate, Oxycodone Hydrochloride, etc. Therapeutic Areas of the products involve analgesics, addiction treatment, cough treatment, diabetes, epilepsy, vascular, respiratory, and rheumatoid arthritis analgesic.

In addition to our own needs, we are planning to produce Active Pharmaceutical Ingredient (API) in order to meet the needs of other pharmaceutical companies in our country and the demand of the foreign market. With our experienced team in this field, we aim to produce our products in an accredited manner in accordance with international standards such as USP (United States Pharmacopeia), EP (European Pharmacopoeia), BP (British Pharmacopoeia), and in accordance with GMP (Good Manufacturing Practice). While the factory project studies continue, Elvin Pharma continues its R&D studies in the field of Active Pharmaceutical Ingredient (API) and its commercial activities with API sales